Literature DB >> 23232570

A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.

Sarah Hawley1, Ladan Fazli, Jesse K McKenney, Jeff Simko, Dean Troyer, Marlo Nicolas, Lisa F Newcomb, Janet E Cowan, Luis Crouch, Michelle Ferrari, Javier Hernandez, Antonio Hurtado-Coll, Kyle Kuchinsky, Janet Liew, Rosario Mendez-Meza, Elizabeth Smith, Imelda Tenggara, Xiaotun Zhang, Peter R Carroll, June M Chan, Martin Gleave, Raymond Lance, Daniel W Lin, Peter S Nelson, Ian M Thompson, Ziding Feng, Lawrence D True, James D Brooks.   

Abstract

Tissue microarrays (TMAs) provide unique resources for rapid evaluation and validation of tissue biomarkers. The Canary Foundation Retrospective Prostate Tissue Microarray Resource used a rigorous statistical design, quota sampling, a variation of the case-cohort study, to select patients for inclusion in a multicenter, retrospective prostate cancer TMA cohort. The study is designed to definitively validate tissue biomarkers of prostate cancer recurrence after radical prostatectomy. Tissue samples from over 1000 participants treated for prostate cancer with radical prostatectomy between 1995 and 2004 were selected at 6 participating institutions in the United States and Canada. This design captured the heterogeneity of screening and clinical practices in the contemporary North American population. Standardized clinical data were collected in a centralized database. The project has been informative in several respects. The scale and complexity of assembling TMAs with over 200 cases at each of 6 sites involved unanticipated levels of effort and time. Our statistical design promises to provide a model for outcome-based studies where tissue localization methods are applied to high-density TMAs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23232570      PMCID: PMC3535290          DOI: 10.1097/PAP.0b013e31827b665b

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  25 in total

Review 1.  Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.

Authors:  Ann Raldow; Daniel A Hamstra; Sung N Kim; James B Yu
Journal:  Cancer Treat Rev       Date:  2010-07-27       Impact factor: 12.111

2.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

3.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

Review 7.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

Authors:  Scott A Tomlins; Anders Bjartell; Arul M Chinnaiyan; Guido Jenster; Robert K Nam; Mark A Rubin; Jack A Schalken
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

8.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

Authors:  Andrew J Stephenson; Michael W Kattan; James A Eastham; Fernando J Bianco; Ofer Yossepowitch; Andrew J Vickers; Eric A Klein; David P Wood; Peter T Scardino
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

9.  Pathologic stage migration has slowed in the late PSA era.

Authors:  Fei Dong; Alwyn M Reuther; Cristina Magi-Galluzzi; Ming Zhou; Patrick A Kupelian; Eric A Klein
Journal:  Urology       Date:  2007-11       Impact factor: 2.649

10.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.

Authors:  Lisa F Newcomb; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Peter S Nelson; Ian M Thompson; Daniel W Lin
Journal:  Urology       Date:  2009-09-16       Impact factor: 2.649

View more
  15 in total

1.  Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

Authors:  James D Brooks; Wei Wei; Jonathan R Pollack; Robert B West; Jun Ho Shin; John B Sunwoo; Sarah J Hawley; Heidi Auman; Lisa F Newcomb; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin E Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Jesse K McKenney; Ziding Feng; Ladan Fazli
Journal:  Prostate       Date:  2016-06-21       Impact factor: 4.104

2.  Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland Analysis.

Authors:  Weisi Xie; Nicholas P Reder; Can Koyuncu; Patrick Leo; Sarah Hawley; Hongyi Huang; Chenyi Mao; Nadia Postupna; Soyoung Kang; Robert Serafin; Gan Gao; Qinghua Han; Kevin W Bishop; Lindsey A Barner; Pingfu Fu; Jonathan L Wright; C Dirk Keene; Joshua C Vaughan; Andrew Janowczyk; Adam K Glaser; Anant Madabhushi; Lawrence D True; Jonathan T C Liu
Journal:  Cancer Res       Date:  2021-12-01       Impact factor: 13.312

3.  Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Authors:  M S Tretiakova; W Wei; H D Boyer; L F Newcomb; S Hawley; H Auman; F Vakar-Lopez; J K McKenney; L Fazli; J Simko; D A Troyer; A Hurtado-Coll; I M Thompson; P R Carroll; W J Ellis; M E Gleave; P S Nelson; D W Lin; L D True; Z Feng; J D Brooks
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

4.  PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Authors:  Tamara L Lotan; Wei Wei; Carlos L Morais; Sarah T Hawley; Ladan Fazli; Antonio Hurtado-Coll; Dean Troyer; Jesse K McKenney; Jeffrey Simko; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Ziding Feng; James D Brooks
Journal:  Eur Urol Focus       Date:  2016-06

5.  Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.

Authors:  James D Brooks; Wei Wei; Sarah Hawley; Heidi Auman; Lisa Newcomb; Hilary Boyer; Ladan Fazli; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Ziding Feng; Jesse K McKenney
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

6.  Prostate-specific RNA aptamer: promising nucleic acid antibody-like cancer detection.

Authors:  Karina Marangoni; Adriana F Neves; Rafael M Rocha; Paulo R Faria; Patrícia T Alves; Aline G Souza; Patrícia T Fujimura; Fabiana A A Santos; Thaise G Araújo; Laura S Ward; Luiz R Goulart
Journal:  Sci Rep       Date:  2015-07-15       Impact factor: 4.379

7.  A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.

Authors:  Dean A Troyer; Tamara Jamaspishvili; Wei Wei; Ziding Feng; Jennifer Good; Sarah Hawley; Ladan Fazli; Jesse K McKenney; Jeff Simko; Antonio Hurtado-Coll; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; James D Brooks; Jeremy A Squire
Journal:  Prostate       Date:  2015-05-04       Impact factor: 4.104

8.  Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

Authors:  Tamara L Lotan; Wei Wei; Olga Ludkovski; Carlos L Morais; Liana B Guedes; Tamara Jamaspishvili; Karen Lopez; Sarah T Hawley; Ziding Feng; Ladan Fazli; Antonio Hurtado-Coll; Jesse K McKenney; Jeffrey Simko; Peter R Carroll; Martin Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; James D Brooks; Raymond Lance; Dean Troyer; Jeremy A Squire
Journal:  Mod Pathol       Date:  2016-05-13       Impact factor: 7.842

Review 9.  MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.

Authors:  Gloria Bertoli; Claudia Cava; Isabella Castiglioni
Journal:  Int J Mol Sci       Date:  2016-03-22       Impact factor: 5.923

10.  Acid ceramidase induces sphingosine kinase 1/S1P receptor 2-mediated activation of oncogenic Akt signaling.

Authors:  T H Beckham; J C Cheng; P Lu; Y Shao; D Troyer; R Lance; S T Marrison; J S Norris; X Liu
Journal:  Oncogenesis       Date:  2013-06-03       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.